HFB-301001 is under clinical development by HiFiBiO Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HFB-301001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HFB-301001 overview

HFB-301001 is under development for the treatment of solid tumors, soft tissue sarcoma, renal cell carcinoma, uterine carcinosarcoma, hepatocellular carcinoma, head and neck squamous cell carcinoma and melanoma. It is administered through intravenous route. The drug candidate acts by targeting OX40 receptor and is developed based on drug intelligent science (DIS) platform.

HiFiBiO Therapeutics overview

HiFiBiO Therapeutics, a biotechnology company that engaged in providing antibody drug discovery services. The company is headquartered in United States.

For a complete picture of HFB-301001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.